Virginia is moving to fix one of the most dangerous gaps in addiction care: the moment an opioid-dependent patient is stabilized in an emergency room and then sent home with little more than a referral slip.
The state's Department of Medical Assistance Services (DMAS), Virginia's Medicaid agency, is offering funding to hospitals and health systems across the state to launch or expand what are called discharge bridge programs. The idea is straightforward: when someone shows up at an ER after an overdose, in withdrawal, or with other opioid-related complications, staff connect them with medication-assisted treatment, peer recovery support, and community services before they walk out the door, not after.
Research has shown that ER visits are a narrow but powerful opening. Patients are medically stabilized and in contact with healthcare workers, but historically that contact has rarely translated into treatment. A landmark 2015 study published in JAMA found that starting patients on buprenorphine in the ED and arranging a handoff to outpatient care roughly doubled treatment engagement at 30 days compared to simply providing a referral.
Virginia has particular reason to pursue that window aggressively. Fatal overdoses in the state climbed from roughly 900 in 2016 to over 2,700 in 2021, with fentanyl now involved in about 80 percent of deaths. The epidemic has hit the state unevenly: Southwest Virginia's Appalachian coal communities were among the earliest saturated with prescription opioids in the early 2000s, while urban areas like Richmond, Norfolk, and Northern Virginia have faced more recent fentanyl surges.
The funding almost certainly comes from opioid litigation settlements with manufacturers, distributors, and pharmacy chains. Virginia is expected to receive roughly $1 billion over 18 years from those agreements, administered through the Virginia Opioid Abatement Authority, which the General Assembly created in 2021. Emergency department bridge programs are explicitly listed as a priority use under the national settlement framework.
DMAS is requiring that any program funded through this round be built to last. Hospitals receiving money must demonstrate a plan to keep the program running after the initial grant period ends, whether through Medicaid billing, hospital operating budgets, or other sources. That sustainability requirement reflects a hard lesson from earlier federal grant cycles, when programs funded by SAMHSA and other agencies often collapsed once startup money ran out.
Having DMAS, rather than a standalone grant program, administer the funding matters. Virginia expanded Medicaid in 2019, adding around 500,000 enrollees, many in demographics hit hardest by opioid use disorder. The Medicaid agency is positioned to build the billing infrastructure that could make bridge services a permanent, reimbursable part of hospital care, similar to what happened with Virginia's nationally recognized ARTS program, which redesigned Medicaid coverage for addiction treatment starting in 2017.
The challenge will be different depending on where hospitals are located. Major academic centers like VCU Health and UVA Health have addiction medicine specialists who can staff bridge programs. Rural critical access hospitals in Southwest Virginia and the Shenandoah Valley often don't, even though those communities may need the services most. How DMAS structures support for smaller and rural applicants will shape whether the program reaches the places the opioid crisis hit first and hardest.
Applications opened May 1. Which hospitals receive funding, and how quickly programs can be stood up, will determine whether the model moves beyond pilots and becomes a standard part of how Virginia emergency rooms handle overdose patients.
